Seaport TherapeuticsSPTX +10.37%11 Current Ratio is 17.46 as of Dec. 2025, which is 23% below its 10-year median of 22.64. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Seaport Therapeutics ranks better than 89.62% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Seaport Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 17.46.
Seaport Therapeutics has a current ratio of 17.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Seaport Therapeutics's Current Ratio or its related term are showing as below:
SPTX'
s Current Ratio Range Over the Past 10 Years
Min: 17.46 Med: 22.64 Max: 27.82
Current: 17.46
During the past 2 years, Seaport Therapeutics's highest Current Ratio was 27.82. The lowest was 17.46. And the median was 22.64.
SPTX's Current Ratio is ranked better than 89.62% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs SPTX: 17.46
Seaport Therapeutics (NAS:SPTX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Seaport Therapeutics Current Ratio Related Terms
Seaport Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Seaport Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seaport Therapeutics Current Ratio Chart
Seaport Therapeutics Annual Data
Trend
Dec24
Dec25
Current Ratio
27.82
17.46
Seaport Therapeutics Semi-Annual Data
Dec24
Dec25
Current Ratio
27.82
17.46
SPTX vs LXRX, DRTS, MGTX: Current Ratio Comparison
For the Biotechnology subindustry, Seaport Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seaport Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Seaport Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seaport Therapeutics (SPTX) has a Current Ratio of 17.46 as of Dec. 2025. This is 23% below median its historical median of 22.64. Over the past decade, Seaport Therapeutics' Current Ratio has ranged from 17.46 to 27.82. According to the industry distribution chart, Seaport Therapeutics ranks #147 out of 1416 companies in the Biotechnology industry, placing it in the top 10.4%.
Is Seaport Therapeutics' Current Ratio too high?
Seaport Therapeutics' current Current Ratio of 17.46 is 23% below median its 10-year median of 22.64. Over the past 10 years, this metric has ranged from a low of 17.46 to a high of 27.82. The Biotechnology industry median Current Ratio is 3.89. Seaport Therapeutics' value of 17.46 is 349.4% above this industry median. Based on the distribution chart, Seaport Therapeutics ranks #147 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Current Ratio compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #147 out of 1416 companies for Current Ratio. This places Seaport Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Seaport Therapeutics' value of 17.46 is 349.4% above this benchmark. Historically, Seaport Therapeutics' own Current Ratio has ranged from 17.46 to 27.82 over the past decade. While the company's 10-year median is 22.64 vs. the industry median of 3.89, Seaport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seaport Therapeutics's current Current Ratio of 17.46 is 349.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seaport Therapeutics's current Current Ratio is 17.46, which is 23% below median its own 10-year median of 22.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Current Ratio of 17.46. The current Current Ratio is 17.46, which is 23% below median its 10-year median of 22.64 and 349.4% above the Biotechnology industry median of 3.89. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Current Ratio is 17.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score
Get the complete analysis for SPTX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPTX has been successfully added to your 